公开(公告)号：WO2012158960A3

公开(公告)日：2012-11-22

申请号：PCT/US2012/038425

申请日：2012-05-17

Applicant: H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. ,  INTEZYNE TECHNOLOGIES INC. ,  ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA ,  BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM ,  GILLIES, Robert, J. ,  MORSE, David, L. ,  BARKEY, Natalie, M. ,  SILL, Kevin, N. ,  VAGNER, Josef ,  TAFRESHI, Narges, K. ,  SESSLER, Jonathan, L. ,  PREIHS, Christian

Inventor： GILLIES, Robert, J. ,  MORSE, David, L. ,  BARKEY, Natalie, M. ,  SILL, Kevin, N. ,  VAGNER, Josef ,  TAFRESHI, Narges, K. ,  SESSLER, Jonathan, L. ,  PREIHS, Christian

IPC: C07K7/06 ,  C07K7/08 ,  C07K5/10 ,  A61K38/08 ,  A61K38/10 ,  A61K9/127 ,  G01N33/574 ,  A61P35/00

Abstract: The subject invention pertains to a modified MCIR peptide ligand comprising a peptide that is a melanocortin 1 receptor (MCIR) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MCIR peptide ligand can be coupled, e.g. , via a click reaction with a complementary click functionality attached, to a moiety to form an MClR-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MCIR. The subject invention also pertains to a MCIR peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MCIR or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

公开(公告)号：WO2021150871A1

公开(公告)日：2021-07-29

申请号：PCT/US2021/014580

申请日：2021-01-22

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA ,  ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY

Inventor： KHANNA, May ,  SANCHEZ, Jonathan Lares ,  GOKHALE, Vijay ,  ODDO, Salvatore

IPC: A61K31/44 ,  A61K31/4375 ,  A61P25/28

Abstract: This invention relates generally to neurodegenerative diseases and conditions (e.g., Alzheimer's disease) characterized with aberrant RIPK1/RIPK3 binding, RIPK3/MLKL binding, necrosome formation, and/or necroptosis activation. This invention further relates to methods and compositions for treating such neurodegenerative diseases and conditions with pharmaceutical compositions comprising agents capable of inhibiting RIPK1/RIPK3 binding and/or RIPK3/MLKL binding.

公开(公告)号：WO2020081441A1

公开(公告)日：2020-04-23

申请号：PCT/US2019/056091

申请日：2019-10-14

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY ,  BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA

Inventor： FERRY, David ,  WHITESIDE, Vincent ,  SELLERS, Ian, R.

IPC: H01L31/02 ,  H01L31/0352 ,  H01L31/036 ,  H01L31/068 ,  H01L31/0687 ,  H01L31/072 ,  H01L31/0725 ,  H01L31/09 ,  H01L31/101

Abstract: A photovoltaic device configured to substantially avoid radiative recombination of photo-generated carriers, reduce loss of energy of the photo-generated carriers through the phonon emission, extract photo-generated carriers substantially exclusively from the multi-frequency satellite valley(s) of the bandstructure of the used semiconductor material as opposed to the single predetermined extremum of the bandstructure. Methodologies of fabrication and operation of such a device.

公开(公告)号：WO2019027945A1

公开(公告)日：2019-02-07

申请号：PCT/US2018/044473

申请日：2018-07-31

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA ,  ARIZONA BOARD OF REGENTS ON BEHALF OF THE NORTHERN ARIZONA UNIVERSITY

Inventor： HEIMARK, Ronald L. ,  GUEST, Kelsey ,  WILDER, Jason ,  WARE, Virginia ,  LAUKAITIS, Christina

IPC: C12N15/11 ,  C12N15/113 ,  G01N33/574 ,  G06F19/22

CPC classification number: C12N15/11 ,  C12N15/113 ,  G01N33/574

Abstract: The invention disclosed herein generally relates to genotyping one or more single nucleotide polymorphisms (SNPs) to stratify cancer risk and/or prognosis.

公开(公告)号：WO2018112391A8

公开(公告)日：2018-06-21

申请号：PCT/US2017/066779

申请日：2017-12-15

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA ,  OLA, Antonius ,  S.M. YEE, Samantha

Inventor： OLA, Antonius ,  S.M. YEE, Samantha ,  MOOBERRY, Susan, L. ,  RISINGER, April, L. ,  CICHEWICZ, Robert, H. ,  DU, Lin ,  LI, Jing ,  PENG, Jiangnan

IPC: A61K31/585 ,  A61K36/894

Abstract: The present disclosure relates to the fields of medicine and pharmaceuticals. In particular, the invention relates to the identification of epoxytaccalonolide microtubule stabilizers for use in inhibiting cell proliferation and disrupting normal cellular microtubule processes leading to cell death. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：WO2018014019A2

公开(公告)日：2018-01-18

申请号：PCT/US2017/042367

申请日：2017-07-17

Applicant: THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY OFFICE OF INTELECTUAL PROPERTY MANAGEMENT TECHNOLOGY, DEVELOPMENT CENTER ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA

Inventor： PIAO, Daqing ,  PATEL, Sanjay

IPC: A61B1/04 ,  G06T7/00

CPC classification number: A61B5/0059 ,  A61B5/0075 ,  A61B5/0084 ,  G01N21/4795

Abstract: Taught herein is a new contact-based optical imaging technology, en-face differential optical topography ( en-face DOT), which performs real-time visualization of subsurface tissue heterogeneity within a depth up to 3mm and over a 9.5mm diameter FOV with a modest mm-level lateral resolution. An embodiment of the probe fits in a 12mm port and houses at its maximum 128 copper-coated 750μηι fibers that form radially alternating illumination (70 fibers) and detection (58 fibers) channels. By simultaneously illuminating the 70 source channels of the laparoscopic probe that is in contact with a scattering medium and concurrently measuring the light diffusely propagated to the 58 detector channels, the presence of near-surface optical heterogeneities can be resolved in an en-face 9.5mm field-of-view in real-time. Visualization of subsurface margin of strong attenuation contrast at a depth up to 3 mm is demonstrated at one wavelength at a frame rate of 1.3 Hz.

Abstract translation: 这里教授了一种新的基于接触的光学成像技术，即面对差分光学地形学（en-face DOT），其执行地下组织异质性的实时可视化 深度达3毫米，超过直径9.5毫米的FOV，并具有适中的毫米级横向分辨率。 探针的一个实施例适合于12mm端口并且容纳最多128个铜涂布的750μm光纤，其形成径向交替照明（70个光纤）和检测（58个光纤）通道。 通过同时照射与散射介质接触的腹腔镜探头的70个源通道并且同时测量漫散射传播到58个检测器通道的光，可以在内窥镜中解决近表面光学异质性的存在， 面对9.5毫米的实时视野。 在1.3Hz的帧速率下在一个波长处证实在深达3mm的强衰减对比度下的下表面边缘的可视化。

公开(公告)号：WO2012139080A3

公开(公告)日：2012-10-11

申请号：PCT/US2012/032649

申请日：2012-04-06

Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  Alzeca Biosciences, LLC ,  Board Of Regents of the University of Houston System ,  Texas Children's Hospital ,  ANNAPRAGADA, Ananth ,  ERIKSEN, Jason, L. ,  TANIFUM, Eric, A. ,  DASGUPTA, Indrani ,  COOK, Stephen, C.

Inventor： ANNAPRAGADA, Ananth ,  ERIKSEN, Jason, L. ,  TANIFUM, Eric, A. ,  DASGUPTA, Indrani ,  COOK, Stephen, C.

IPC: A61K49/18

Abstract: Lipid-based nanoparticle compositions are provided. The compositions generally comprise lipid-hydrophilic polymer-amyloid binding ligand conjugates, and may be liposomal compositions. The compositions, including the liposomal compositions comprising, may be useful for imaging and/or the treatment of amyloid-β plaque deposits characteristic of Alzheimer's Disease. One such method for imaging amyloid deposits in a patient is provided, the method comprising: introducing into the patient a detectable quantity of a liposomal composition comprising a lipid-hydrophilic polymer-Formula I ligand conjugate.

公开(公告)号：WO2009052467A1

公开(公告)日：2009-04-23

申请号：PCT/US2008/080429

申请日：2008-10-20

Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  ARIZONA BOARD OF REGENTS, ACTING ON BEHALF OF THE UNIVERSITY OF ARIZONA ,  POWIS, Garth ,  IHLE, Nathan

Inventor： POWIS, Garth ,  IHLE, Nathan

IPC: G01N33/50

CPC classification number: G01N33/5091 ,  A61K31/366 ,  A61K31/685 ,  A61K31/7064 ,  A61K31/7105

Abstract: The invention described herein is directed to methods for identifying an individual who may be resistant or susceptible to phosphatidylinositol-3-kinase inhibitors, methods of treating an individual by identifying individuals who are resistant or susceptible to phosphatidylinositol-3-kinase inhibitors, and kits for testing individuals for resistance or susceptibility to phosphatidylinositol-3-kinase inhibitors.

Abstract translation: 本文描述的发明涉及用于鉴定可能对磷脂酰肌醇-3-激酶抑制剂具有抗性或易感性的个体的方法，通过鉴定对磷脂酰肌醇-3-激酶抑制剂具有抗性或易感性的个体来治疗个体的方法，以及用于 测试个体对磷脂酰肌醇-3-激酶抑制剂的抗药性或易感性。

公开(公告)号：WO2008028055A2

公开(公告)日：2008-03-06

申请号：PCT/US2007/077264

申请日：2007-08-30

Applicant: THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA ,  HUHNKE, Raymond, L. ,  LEWIS, Randy, S. ,  TANNER, Ralph, S.

Inventor： HUHNKE, Raymond, L. ,  LEWIS, Randy, S. ,  TANNER, Ralph, S.

IPC: C12P7/06 ,  C12N1/21

CPC classification number: C12R1/145 ,  C12P7/065 ,  C12P7/08 ,  Y02E50/17

Abstract: A novel clostridia bacterial species (Clostridium ragsdalei, ATCC BAA-622 and/or PTA-7826, "P11") is provided. P11 is capable of synthesizing, from waste gases, products which are useful as biofuel. In particular, P11 can convert CO to ethanol. Thus, this novel bacterium transforms waste gases (e.g. syngas and refinery wastes) into useful products. P11 also catalyzes the production of acetate.

Abstract translation: 提供了一种新型的梭菌菌种（Clostridium ragsdalei，ATCC BAA-622和/或PTA-7826，“P11”）。 P11能够从废气中合成可用作生物燃料的产品。 特别地，P11可将CO转化为乙醇。 因此，这种新型细菌将废气（例如合成气和炼厂废​​物）转化成有用的产物。 P11还催化乙酸盐的生产。

公开(公告)号：WO2002041871A3

公开(公告)日：2002-05-30

申请号：PCT/US2001/043292

申请日：2001-11-20

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA ,  LOPEZ-BERESTEIN, Gabriel ,  REMERS, William, A. ,  HERSH, Evan, M.

Inventor： LOPEZ-BERESTEIN, Gabriel ,  REMERS, William, A. ,  HERSH, Evan, M.

IPC: A61K31/396

Abstract: Disclosed are novel compositions comprising a lipid and imexon or a derivative thereof. Also disclosed are liposomal compositions comprising imexon or derivative thereof. Methods for administrating pharmaceutically acceptable compositions comprising a lipid and imexon or a derivative thereof for the treatment of diseases, such as cancer, are also disclosed herein.